Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Free Cash Flow: 2011-2025

Historic Free Cash Flow for Enanta Pharmaceuticals (ENTA) over the last 15 years, with Sep 2025 value amounting to -$32.2 million.

  • Enanta Pharmaceuticals' Free Cash Flow rose 58.93% to -$7.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.2 million, marking a year-over-year increase of 66.74%. This contributed to the annual value of -$32.2 million for FY2025, which is 66.74% up from last year.
  • Enanta Pharmaceuticals' Free Cash Flow amounted to -$32.2 million in FY2025, which was up 66.74% from -$96.7 million recorded in FY2024.
  • In the past 5 years, Enanta Pharmaceuticals' Free Cash Flow ranged from a high of -$32.2 million in FY2025 and a low of -$112.2 million during FY2023.
  • In the last 3 years, Enanta Pharmaceuticals' Free Cash Flow had a median value of -$96.7 million in 2024 and averaged -$80.4 million.
  • As far as peak fluctuations go, Enanta Pharmaceuticals' Free Cash Flow crashed by 1,353.69% in 2021, and later soared by 66.74% in 2025.
  • Yearly analysis of 5 years shows Enanta Pharmaceuticals' Free Cash Flow stood at -$70.7 million in 2021, then decreased by 22.84% to -$86.9 million in 2022, then declined by 29.12% to -$112.2 million in 2023, then grew by 13.81% to -$96.7 million in 2024, then surged by 66.74% to -$32.2 million in 2025.